Azets Corporate Finance advised the shareholders of PharmaReview on securing investment from Bridgepoint

Business overview

PharmaReview, a UK provider of compliance and copy review services for promotional materials used in the life sciences sector, has partnered with Bridgepoint Growth to further support the growth of the business. Terms of the transaction are confidential.

Established in 2011 to solve the problem of inefficient medical review processes in pharma companies, the company is a supplier to some of the world’s largest pharma groups, ensuring that the latter’s promotional materials are medically accurate, make scientific sense, comply with ethical legal and regulatory code requirements, and ensure all claims are backed up with references to accurate and up-to-date underlying sources. 

Perspectives

Commenting on the transaction, PharmaReview co-founder and Director Tessa Pugh, said: “We have reached an inflection point in our business development where the market opportunity for our services is growing quickly and we recognise the benefit of a partner who shares our growth ambitions and can work with us and provide the additional firepower to take the business to the next stage. I’m delighted to welcome Bridgepoint Growth as that new partner.”

Mayank Kanga of Bridgepoint said: “We believe there is a significant opportunity to broaden service offering, either through geographic or service expansion and to invest in the team to allow it to add further value to their clients and to realise the market opportunity open to them.”

Andy Coghlan, Head of Private Equity and International Transactions at Azets commented: "We are delighted to have advised Ralph and Tessa on securing the investment from Bridgepoint. It will be exciting to follow their growth over the next few years. This is our third deal in the Pharma Services arena in the last 2 years as we continue to build our experience in this market."